CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Ozurdex for Diabetic Macular Edema: Clinical Effectiveness, Cost-effectiveness, and Guidelines

Last updated: March 9, 2020
Project Number: RA1092-000
Product Line: Rapid Response
Research Type: Drug
Report Type: Reference List
Result type: Report

Question

  1. What is the clinical effectiveness of dexamethasone intravitreal injection for patients with diabetic macular edema?
  2. What is the clinical evidence regarding the safety of dexamethasone intravitreal injection for patients with diabetic macular edema?
  3. What is the cost-effectiveness of dexamethasone intravitreal injection for patients with diabetic macular edema?
  4. What are the evidence-based guidelines regarding dexamethasone intravitreal injection for the treatment of patients with diabetic macular edema?

Key Message

Two systematic reviews (one with meta-analyses), two randomized controlled trials, and thirteen non-randomized studies were identified regarding the clinical effectiveness and safety of dexamethasone intravitreal injection for patients with diabetic macular edema. Additionally, three evidence-based guidelines were identified regarding dexamethasone intravitreal injection for the treatment of patients with diabetic macular edema.